Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolyPeptide Group AGPLYGF 57 Days Sales Outstanding is 54.99 as of Jun. 2026, which is 24% below its 10-year median of 72.67. GuruFocus rates PLYGF with a GF Score™ of 57/100 and a GF Value™ of $32.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 947 Drug Manufacturers companies, PolyPeptide Group AG ranks better than 72.23% on this metric.
PolyPeptide Group AG (OTCPK:PLYGF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
PolyPeptide Group AG Days Sales Outstanding Related Terms
PolyPeptide Group AG Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLYGF vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's Days Sales Outstanding falls into.
PolyPeptide Group AG Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (PLYGF) has a Days Sales Outstanding of 54.99 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on PolyPeptide Group AG and its competitors. This is 24% below median its historical median of 72.67. Over the past decade, PolyPeptide Group AG's Days Sales Outstanding has ranged from 52.40 to 86.19. According to the industry distribution chart, PolyPeptide Group AG ranks #263 out of 947 companies in the Drug Manufacturers industry, placing it in the top 27.8%.
Is PolyPeptide Group AG's Days Sales Outstanding too high?
PolyPeptide Group AG's current Days Sales Outstanding of 54.99 is 24% below median its 10-year median of 72.67. Over the past 10 years, this metric has ranged from a low of 52.40 to a high of 86.19. The Drug Manufacturers industry median Days Sales Outstanding is 71.92. PolyPeptide Group AG's value of 54.99 is 23.5% below this industry median. Based on the distribution chart, PolyPeptide Group AG ranks #263 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PolyPeptide Group AG has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #263 out of 947 companies for Days Sales Outstanding. This puts PolyPeptide Group AG in the upper half of its industry. The industry median Days Sales Outstanding is 71.92. PolyPeptide Group AG's value of 54.99 is 23.5% below this benchmark. Historically, PolyPeptide Group AG's own Days Sales Outstanding has ranged from 52.40 to 86.19 over the past decade. While the company's 10-year median is 72.67 vs. the industry median of 71.92, PolyPeptide Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.92, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPeptide Group AG's current Days Sales Outstanding of 54.99 is 23.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on PolyPeptide Group AG and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPeptide Group AG's current Days Sales Outstanding is 54.99, which is 24% below median its own 10-year median of 72.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $32.02, compared to a current price of $54.42 — trading 70% above its estimated fair value. The current Days Sales Outstanding is 54.99, which is 24% below median its 10-year median of 72.67 and 23.5% below the Drug Manufacturers industry median of 71.92. PolyPeptide Group AG's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current Days Sales Outstanding is 54.99 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of $54.42 is trading 70% above its estimated GF Value™ of $32.02.
GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.
Key valuation signals for PLYGF:
Days Sales Outstanding: 54.99 (24% below median its 10-year median of 72.67)
GF Value™: $32.02 vs. price of $54.42 (70% above fair value)
Industry Position: 23.5% below the Drug Manufacturers median (#263 of 947)
No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
57GF Score
Get the complete analysis for PLYGF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYGF has been successfully added to your 
